Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
- PMID: 12869452
- PMCID: PMC165707
- DOI: 10.1136/bmj.327.7407.128
Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies
Abstract
Objectives: To quantify the risk of Alzheimer's disease in users of all non-steroidal anti-inflammatory drugs (NSAIDs) and users of aspirin and to determine any influence of duration of use.
Design: Systematic review and meta-analysis of observational studies published between 1966 and October 2002 that examined the role of NSAID use in preventing Alzheimer's disease. Studies identified through Medline, Embase, International Pharmaceutical Abstracts, and the Cochrane Library.
Results: Nine studies looked at all NSAIDs in adults aged > 55 years. Six were cohort studies (total of 13 211 participants), and three were case-control studies (1443 participants). The pooled relative risk of Alzheimer's disease among users of NSAIDs was 0.72 (95% confidence interval 0.56 to 0.94). The risk was 0.95 (0.70 to 1.29) among short term users (< 1 month) and 0.83 (0.65 to 1.06) and 0.27 (0.13 to 0.58) among intermediate term (mostly < 24 months) and long term (mostly > 24 months) users, respectively. The pooled relative risk in the eight studies of aspirin users was 0.87 (0.70 to 1.07).
Conclusions: NSAIDs offer some protection against the development of Alzheimer's disease. The appropriate dosage and duration of drug use and the ratios of risk to benefit are still unclear.
Figures
Comment in
-
Effect of NSAIDs on risk of Alzheimer's disease: confounding factors were not discussed.BMJ. 2003 Sep 27;327(7417):751; author reply 751-2. doi: 10.1136/bmj.327.7417.751-b. BMJ. 2003. PMID: 14512494 Free PMC article. No abstract available.
-
Effect of NSAIDs on risk of Alzheimer's disease: conclusions on NSAIDs and Alzheimer's disease were overstated.BMJ. 2003 Sep 27;327(7417):752. doi: 10.1136/bmj.327.7417.752. BMJ. 2003. PMID: 14512499 Free PMC article. No abstract available.
Similar articles
-
Anti-inflammatory drugs and risk of Alzheimer's disease: an updated systematic review and meta-analysis.J Alzheimers Dis. 2015;44(2):385-96. doi: 10.3233/JAD-141506. J Alzheimers Dis. 2015. PMID: 25227314 Review.
-
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review.Neuroepidemiology. 2004 Jul-Aug;23(4):159-69. doi: 10.1159/000078501. Neuroepidemiology. 2004. PMID: 15279021 Review.
-
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease.N Engl J Med. 2001 Nov 22;345(21):1515-21. doi: 10.1056/NEJMoa010178. N Engl J Med. 2001. PMID: 11794217
-
Risk of Alzheimer's disease and duration of NSAID use.Neurology. 1997 Mar;48(3):626-32. doi: 10.1212/wnl.48.3.626. Neurology. 1997. PMID: 9065537 Clinical Trial.
-
No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies.Neurology. 2008 Jun 10;70(24):2291-8. doi: 10.1212/01.wnl.0000313933.17796.f6. Epub 2008 May 28. Neurology. 2008. PMID: 18509093 Free PMC article.
Cited by
-
Cyclodextrin-Containing Drug Delivery Systems and Their Applications in Neurodegenerative Disorders.Int J Mol Sci. 2024 Oct 9;25(19):10834. doi: 10.3390/ijms251910834. Int J Mol Sci. 2024. PMID: 39409162 Free PMC article. Review.
-
Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.Curr Drug Targets. 2024;25(13):885-908. doi: 10.2174/0113894501323980240815113851. Curr Drug Targets. 2024. PMID: 39177131 Review.
-
Naringenin ameliorates amyloid-β pathology and neuroinflammation in Alzheimer's disease.Commun Biol. 2024 Jul 28;7(1):912. doi: 10.1038/s42003-024-06615-6. Commun Biol. 2024. PMID: 39069528 Free PMC article.
-
Non-coding RNAs involved in the molecular pathology of Alzheimer's disease: a systematic review.Front Neurosci. 2024 Jun 28;18:1421675. doi: 10.3389/fnins.2024.1421675. eCollection 2024. Front Neurosci. 2024. PMID: 39005845 Free PMC article.
-
REsveratrol for VAscular cognitive impairment investigating cerebral Metabolism and Perfusion (REVAMP trial): a study protocol for a randomized, double-blind, placebo-controlled trial.Front Nutr. 2024 Apr 23;11:1359330. doi: 10.3389/fnut.2024.1359330. eCollection 2024. Front Nutr. 2024. PMID: 38716073 Free PMC article.
References
-
- In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijin CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345: 1515-21. - PubMed
-
- Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Brietner JC, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 2002;59: 880-6. - PubMed
-
- Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001;345: 1567-8. - PubMed
-
- Fourrier A, Letenneur L, Begaud B, Dartigues JF. Nonsteroidal anti-inflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996;49: 1201. - PubMed
-
- McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47: 425-32. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical